What's Inside


Rad Onc Home

The Department of Radiation Oncology
is part of the
ALRT Administrative
Center.

Learn more about ALRT

Other ALRT Departments

Anesthesiology

Laboratory Medicine and Pathology

Radiology

University of Minnesota Physicians Clinic Appointment and Referral Information


 

 
  Home > Faculty and Staff > Radiation Biology and Molecular Cancer Therapeutics > Daniel A. Vallera, PH.D.
 

Daniel A. Vallera, PH.D.

email: valle001@umn.edu


Field of Specialization:
Immunology, Bone Marrow Transplantation, and
Cancer Research

EDUCATION

Ohio State UniversityMicrobiology, Ph.D.1978
Ohio State UniversityMicrobiology, M.S.1975
Ohio State UniversityMicrobiology, B.S.1973
Columbus, Ohio

APPOINTMENTS

1989-present Professor of Therapeutic Radiology

Director of Section on Experimental Cancer Immunology, University of Minnesota

1995-present University of Minnesota Cancer Center

1984-1989 Associate Professor of Therapeutic Radiology, University Minnesota, Tenured - 1986

1981-1984 Assistant Professor of Therapeutic Radiology and University of Minnesota

1979-1980 Research Associate, Department of Laboratory Medicine/Pathology, University of Minnesota

1978-1979 Postdoctoral Fellow, Department of Surgery,

University of Minnesota

Directorships
Section of Experimental Cancer Immunology, Therapeutic Radiology

Cancer Research Center Animal Facility

GRANTS

Current grant support

ACTIVE-NIH

PROJECT# (PI): NIH-RO1 CA82154 DATES : 4/1/00-6/30/08
SOURCE: NIH/NCI
TITLE :Retroviral Immunotoxins for Leukemia
GOAL: The major goals of this project are to develop a system of gene therapy for delivery of immunotoxin genes to tumors using T cells as delivery vehicles.

PROJECT# (PI) NIH RO1 CA36725 (Daniel A. Vallera, Ph.D.) DATES :8/1/97-7/31/05
SOURCE: NIH/NCI
TITLE :Immunotoxins in bone marrow transplantation
GOAL: The goal of this grant is to investigate methods to improve the anti-GVHD effect of various molecular constructs of an anti-CD3 sFv fusion immunotoxin.

PROJECT# (PI): DE-FG02-96ER62181 (Donald J. Buchsbaum, Ph.D.) Dr. Vallera is a co-investigator. DATES :8/1/97-3/31/04
SOURCE: U.S. Department of Energy, Biological and Environmental Research Program.
TITLE :therapy of Experimental Colon and Ovarian Cancer
GOAL: The goal of this grant is to investigate development of radiolabeled immunotoxins for the therapy of colon and ovarian cancer.

ACTIVE-LOCAL

PROJECT# (PI): Immunotoxins for Brain Cancer Therapy (Daniel A. Vallera, Ph.D.)
DATES : 7/1/99-6/30/04
SOURCE: Neurosurgery Brain Cancer Research
TITLE :Immunotoxins for Brain Cancer Therapy
GOAL: The goal of this grant is to investigate development of immunotoxins for localized therapy of brain cancer. This is a collaborative effort with Dr.Walter Hall, Professor of Neurosurgery. Dr. Hall has invented a catheter that will permit us to administer recombinant drugs intracranially.

SOURCE: Cancer Center/Academic Health Sciences DATES : 7/1/00-3/31/04
TITLE :Development of a clinical antibody radiolabeling facility for cancer therapy
GOAL: The goal is to get a facility on line that has the capacity to perform clinical antibody labelings with radionuclides such as 90 Y for the therapy of ALL, AML, and lymphoma.

Past grant support

Leukemia Research Fund (Local). Retroviral immunotoxins for Leukemia. The goal of this grant is to investigate development of retroviral immunotoxins for treatement of cancer. This served as a seed grant to obtain the data necessary to procure NIH funds. NIH grant NIH-RO1 CA82154 was funded as a result. DATES : 7/198-6/30/00

National Cancer Institute, National Institutes of Health. Cancer Center Support Grant. John Kersey, M.D. Principal Investigator. 1P30CA7759-01. Dr. Vallera was a co-leader of the knockout mouse core project and received 5% salary support. 4/1/98-3/31/03

National Cancer Institute, National Institutes of Health. NIH RO1 HL55209. Daniel A. Vallera, Coinvestigator. Bruce R. Blazar, Principal Investigator. 9/15/95-8/31/99.The goal is to explore the cellular mechanism of lung injury post-bone marrow transplantation using knockout mice.

Children's Cancer Research Fund. Daniel A. Vallera, Principal Investigator. "Genetic alterations designed to reduce toxicity of DT 390 anti-CD3sFv". The goal is to develop new recombinant immunotoxins that will be of benefit in treating graft-versus-host-disease.

Minnesota Medical Foundation. Daniel A. Vallera, Principal Investigator. "New Recombinant fusion toxins for GVHD therapy."

Immunex Corporation. Daniel A. Vallera, Principal Investigator. Recombinant cytokines. Special grant for determining the effects of recombinant growth factors on engraftment.

Hubert H. Humphrey Cancer Research Fund. Daniel A. Vallera, Principal Investigator. Award period unspecified.

National Cancer Institute, National Institutes of Health. R01-CA-31618. Daniel A. Vallera, Principal Investigator. "Irradiation and the immune system." Awarded February 1, 1982 - January 31, 1996.

National Institutes of Health. P01-CA-21737. Bone Marrow Transplantation Program Project Center Grant. Daniel A. Vallera, Project Leader. John H. Kersey, M.D. and Norma Ramsay, M.D., Principal Investigators. "Murine Bone Marrow Transplantation Across the Minor Histocompatibility Barriers." March 1, 92 - February 29, 1997.

National Institutes of Health. RFP N01-AI-85002. "Acquisition of data for developing improved strategies for conditioning of bone marrow, and to facilitate the transplantation of immune cell depleted marrow grafts." Daniel A. Vallera, Co-principal investigator. September 30, 1988 - September 29, 1993.

American Diabetes Association/ Minnesota affiliate. Joan Siskind Award. Prevention and Therapy of Experimental Autoimmune Diabetes.

Minnesota Medical Foundation. Daniel A. Vallera, Principal Investigator. Gynecology/Immunotoxins. Award period unspecified.

Minnesota Medical Foundation. Daniel A. Vallera, Principal Investigator. Therapeutic Radiology/Immunotoxins. Award period unspecified.

American Cancer Society Research Investigation Grant. IM-502. Daniel A. Vallera, Principal Investigator. "Therapy of experimental human leukemia/lymphoma using radioimmunotoxins." Awarded January 1, 1988 - December 31, 1990.

Cetus Corporation. Daniel A. Vallera, Principal Investigator. Special grant for development of novel immunotoxin strategies. July 1, 1987 - June 30, 1989.

Leukemia Society of America Scholar Award. "Monoclonal antibodies linked to ricin: reagents for use in human allogeneic and autologous bone marrow transplantation for leukemia." July 1, 1983 - June 30, 1988. Salary award for career development.

Minnesota Medical Foundation Special Research and Equipment Grant. Daniel A. Vallera, Principal Investigator. "The FACScan flow cytometer: an integral research instrument in immunology, hematology, and oncology." Awarded 1988.

Minnesota Medical Foundation Research Grant. "In vivo use of immunotoxins in human bone marrow transplantation." Daniel A. Vallera, P.I. July 1, 1986 - June 30, 1987.

American Cancer Society Research Investigation Grant. Daniel A. Vallera, P.I. "Immunotoxins in autologous bone marrow transplantation for treatment of human leukemia." July 1, 1984 - June 30, 1986.

Cetus Corporation. "Immunotoxin pretreatment of donor marrow for prevention of graft-versus-host disease: Clinical studies." Daniel A. Vallera, P.I. December 1, 1984 - November 30, 1987.

Department of Laboratory Medicine/Pathology Special Grant. Daniel A. Vallera, P.I. 1984-85.

Graduate School Special Equipment Grant. Daniel A. Vallera, P.I. July 1, 1984 - June 30, 1985.

Minnesota Medical Foundation Special Research and Equipment Grant. Daniel A. Vallera, P.I. "Immunotoxins for autologous bone marrow transplantation in leukemia." September 1, 1984 - August 31, 1985.

Minnesota Medical Foundation Equipment Grant. Daniel A. Vallera, P.I. "Anti-human T cell monoclonal antibodies linked to toxin ricin as possible reagents for GVHD prophylaxis." July 1, 1982 - June 30, 1983. .

Graduate School Grant. Daniel A. Vallera, P.I. "Generation of radiation chimeras across major histocompatibility barriers: Anti-Thy-1.2 plus complement treatment of donor cells as therapy for graft-versus-host disease." July 1, 1981 - June 30, 1982.

Minnesota Medical Foundation Research Grant. Daniel A. Vallera, P.I. "Suppression of the generation of anti-tumor cell mediated cytotoxicity by mitogenically activated suppressor B cells." May 1, 1979 - April 30, 1980.

Recipient of National Research Service Award. Postdoctoral Fellowship 1979-80.

American Cancer Society, Minnesota Branch. Daniel A. Vallera, P.I. "Suppression of the generation of anti-tumor cell-mediated cytotoxicity by mitogenically activated suppressor B cells." 1978-79.

American Cancer Society, Ohio Branch. Daniel A. Vallera, P.I. "The role of cAMP is anti-tumor cytotoxicity." 1976-78.

CURRENT FACILITIES

Three well-equipped laboratories on the fourth floor of the University of Minnesota Cancer Center Research Building. These facilities are used to conduct research in experimental transplantation and cancer research. The facilities are well suited for therapeutic studies with special accomadations for molecular drug design, retroviruses, protein purification, histologic and immunohistochemical studies, and in utero and adult bone marrow transplantation. Facilities are provided for the housing and care of 5,000-6,000 mice.

Current Personnel

3 full-time technicians
2 part-time student lab attendants
1 Masters student
1 Research Senior Research Associate

TEACHING

Current Trainees

Ph.D. Candidate: Edward Rustamzadeh
Under-graduate University of Minnesota College of Biological Sciences Honors Program: Lindsey Hornikel
Research Associate: Ni Jin, M.D.
Research Associate: Michael Elson

Graduate Faculty Appointments

Ph.D. MD. program
Immunology Training Grant
Bone Marrow Transplantation Biology Training Grant
Microbiology, Immunology, and Molecular Pathobiology Graduate Faculty (MIMP)
Pathobiology Graduate Faculty (Doctoral Program)
Clinical Laboratory Science Graduate Faculty (Master's Program)
Biomedical Science Graduate Faculty

Formal Courses

Radiation Biology 5172 3 cr.
Radiobiology 3172 3 cr.
Pathobiology 8109 5 cr.
Pharmacology 8114 3 cr.
Frontiers of Immunology 8321 5 cr.
Pharmacology 8111 3 cr.
Laboratory Medicine/Pathology 5101 - General Pathology (cr. arr.)
Immunology 5216/5218 5 cr.
Cancer Immunobiology 8218 5cr.
Radiation Biology 5172 5 cr.
Training Faculty Member for the Immunology Training Program
funded by the National Institutes of Health

Participant in University Speaker Programs

Immunobiology Seminar
Pediatric Research Conference
Laboratory Medicine/Pathology Research Seminar
Bone Marrow Transplantation Conference
Transplantation Conference
Therapeutic Radiology Research Seminar
Gynecologic Oncology Concensus Conference
Anatomy Seminar
Microbiology, Immunology, and Pathobiology
Garibaldi Research Conference
Laboratory Medicine Grand Rounds
M.D./Ph.D. Seminar Series
College of Pharmacy Conference
Pediatric Hematology-Oncology Research Conference
Research Animal Resources Series

Participant in Training Workshops

University of Minnesota Conference "Bone Marrow Processing for Transplantation: CurrentPractices and Future Directions." Minneapolis, MN.
American Society for Histocompatibility and Immunogenetics's Region IV Education Workshop.
American Association of Blood Banks: Monoclonal Antibody Workshop.

HONORS and SPECIAL RECOGNITION

Awards

National Research Service Award Fellowship
Hubert H. Humphrey Cancer Research Award
Sponsorship and Support of a Post-Doctoral Fellow awarded by
the Anna Fuller Foundation and the Isreal Cancer Research Fund
Travel Award from NATO to attend the NATO Advanced Studies Institute on"Receptor Mediated Targeting of Drugs" in Sounion Beach, Greece
Travel Award from American Association of Immunologists to attend the Fifth
International Congress of Immunology in Kyoto, Japan
American Cancer Society Junior Faculty Award
Leukemia Society of America Scholar Award
Minnesota Medical Foundation Special Research and Equipment Grant
Editorial Board-Transplantation
Minnesota Medical Foundation Special Research and Equipment Grant
Pierce Immunotoxin Award, presented at the First International Symposium on Immunotoxins, Duke University Medical Center
Joan Soskind Award - American Diabetes Association
American Cancer Society, Scientific Advisory Committee on Immunology and Immunotherapy.
Distinguished Alumnae Award, East Liverpool, Ohio. Voted one of sixteen
alumnus from my home town (population 20,000) that have most
distinguished themselves

Editorial Responsibilities

Editorial Board of Transplantation

Editorial Board of Bone Marrow Transplantation

Ad hoc reviewer for Protein Engineering, Science, Journal of Immunology, Blood, and Cancer Research

Peer Review Responsibilities

Site Visit - Seattle Bone Marrow Transplantation Program: "Marrow Grafting for Treatment of Hematologic Malignancies," submitted by Rainer Storb, M.D. Fred Hutchinson Cancer Research Center, Seattle, WA.

Site Visit - M.D. Anderson Bone Marrow Transplantation Program: "Studies in Autologous Bone Marrow Transplantation," submitted by Karel A. Dicke, M.D. M.D. Anderson Hospital and Tumor Institute, Houston, TX.

Ad hoc reviewer: Experimental Therapeutics - 2, Study Section, Division of Research Grants, National Institutes of Health, Bethesda, MD.

Dana Farber Cancer Institute: "Solid Tumor Autologous Marrow Program," submitted by Emil Frei, III, M.D. Harvard University Medical School, Boston, MA.

Sloan-Kettering Bone Marrow Transplant Service: "Marrow Transplantation in Leukemia and Other Diseases," submitted by Richard J. O'Reilly, M.D. Sloan-Kettering Institute, New York, NY.

Dana Farber Cancer Institute: "Program of studies on the biology and treatment of human leukemia and lymphoma," submitted by Stuart Schlossman, M.D., Harvard University Medical School, Boston, MA.

Member of the cancer immunology study section for the American Cancer Society. University of Texas at Dallas: "Immunotoxins for therapy of lymphoma", submitted by Johnathan Uhr and Ellen Vitetta. University of Texas at Dallas, Dallas, TX.

Site Visit - Seragen, Inc., Boston, MA

Reverse Site Visit - University of Texas at Dallas: "Immunotoxins for therapy of lymphoma", submitted by Johnathan Uhr and Ellen Vitetta. University of Texas at Dallas, Dallas, TX.

American Cancer Society. Scientific Advisory Committee on Immunology and Immunotherapy.

Served as an Expert Reviewer for United States-Isreal Binational Science Foundation

Served as an Expert Reviewer for all abstracts in the area of Experimental Transplantation-GVHD and Neoplasia for the 40th Annual Meeting of the American Society of Hematology, Miami Beach FL.

The Charles Harkin Award for Research in Thyroid Cancer Review Team, National Institutes of Health. Team assesses the merit of intramural research grants

The Charles Harkin Award for Research in Thyroid Cancer Review Team, National Institutes of Health

UNIVERSITY COMMITTEES

Conflict of Interest Review Committee
Animal Advisory Committee
Immunology Working Group Committee
Promotions and Tenure Committee
Vice Chairman IACUC University of Minnesota's Institutional Animal Care and Use Committee
Chairman SPF Task Force
Codirector of the University of Mouse Genetics Facility
Immunology Working Group

MEMBERSHIPS

American Association of Immunologists
Transplantation Society
American Association for the Advancement of
American Society of Hematology

PATENTS

Radiolabeled Fusion Toxins for Cancer Therapy D5854; USSN 08/851,749 (FY96-0013) Issued.

Retroviral Cytokine Immunotoxins U/M Docket: 99077. Filed 6/99.

COMMUNITY SERVICE

Senior Assistant Scout Master, Troop 102 Edina Minnesota. Public service speaking to grade schools and high schools on the use of experimental animals in todays cancer research. At the end of the year I will be taking over as Scout Master of this troop of about 50 excellent young men.



 
What's Inside

Dr. Daniel Vallera     

Notice of Privacy Practices